Apple’s requests to overturn a $634 million patent verdict and secure a new trial in its long-running legal battle with Masimo were denied. Here are the details.
A bit of background
In early 2020, medical technology company Masimo sued Apple, accusing it of stealing trade secrets and infringing patents related to pulse oximetry and other optical health-monitoring technologies used by the Apple Watch.
Since then, the companies have been locked in a sprawling legal battle. In 2023, Masimo secured an International Trade Commission (ITC) ruling that led to a US import ban affecting Apple Watch models equipped with blood oxygen monitoring.
This prompted Apple to temporarily halt sales, later resuming sales of affected models with the blood oxygen feature disabled. In 2025, the company introduced a redesigned feature that measures and calculates sensor data from the Apple Watch on the paired iPhone, with results displayed in the Health app. Masimo subsequently sued US Customs and Border Protection over its decision to allow imports of watches featuring the redesign.
